51. Preliminary comparative analysis of kynurenine pathway metabolites in chronic ketamine users, schizophrenic patients, and healthy controls
- Author
-
Haoyang Lu, Ni Fan, Xiao-Jia Ni, Yayan Luo, Zhaohua Zhang, Yuguan Wen, and Minling Zhang
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,Kynurenine pathway ,Substance-Related Disorders ,Beck Anxiety Inventory ,Kynurenic Acid ,Young Adult ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Kynurenic acid ,Tandem Mass Spectrometry ,Internal medicine ,Humans ,Medicine ,Pharmacology (medical) ,Ketamine ,Chromatography, High Pressure Liquid ,Kynurenine ,Psychiatric Status Rating Scales ,Positive and Negative Syndrome Scale ,business.industry ,Tryptophan ,Beck Depression Inventory ,Middle Aged ,medicine.disease ,030227 psychiatry ,Psychiatry and Mental health ,Endocrinology ,Neurology ,chemistry ,Schizophrenia ,Case-Control Studies ,Female ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
OBJECTIVE The serum kynurenine pathway metabolites kynurenic acid (KYNA), kynurenine (KYN), and tryptophan (TRP) were examined in chronic ketamine users and in schizophrenic patients. The correlations of the metabolites with sociodemographic data, clinical characteristics, and drug use status were analyzed. METHODS Seventy-nine healthy controls, 78 ketamine users, and 80 schizophrenic patients were recruited. Serum TRP, KYN, and KYNA levels were measured by high-performance liquid chromatography following tandem mass spectrometry (MS/MS). Psychotic symptoms were evaluated using the positive and negative syndrome scale (PANSS), the Beck Depression Inventory (BDI), and the Beck Anxiety Inventory (BAI). RESULTS Serum levels of TRP, KYNA, and KYN (in ketamine users only) were lower in ketamine users and schizophrenic patients than in controls (p
- Published
- 2020